Skip to main content
Fig. 2 | BMC Microbiology

Fig. 2

From: Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity

Fig. 2

The gut microbiota actual phylum abundance in healthy, colon-cancer, and Irinotecan groups, as assessed by 16S rRNA metagenomics sequencing. Irinotecan lowered the microbiota actual abundance (a). Alpha diversity estimation in healthy, colon cancer, and Irinotecan treated groups using (b) Shao index showing a significant diversity with p-value 0.019025 [ANOVA] F-value 5.8035, (c) Shannon index showing a significant diversity with p-value 0.027945 [ANOVA] F-value 5.0403. Beta diversity among three groups based on Bray Curtis Index, [PERMANOVA] F-value 1.6378; R-squared 0.22945; p-value 0.032 (d)

Back to article page